The Science of Synergy
KOfactor1 was developed by Young Ko, PhD, at KoDiscovery laboratory. The compounds in KOfactor1 act synergistically to effect a multitude of cellular processes*:
- Helps support changing the expression of genes to promote cellular health*
- Helps support apoptosis (programmed cell death)*
Motivation for Developing KOfactor™ Products
Natural compounds have a role to play in a holistic, multi-targeted approach to restoring health.
“The fields of Nutrition and Metabolism are my passion. I’ve always been fascinated by how what we eat influences our body, specifically, believing that certain natural compounds in plants are medicine. This is why animals instinctually know to eat herbs when they are sick. The compounds in herbs influence our epigenetics and metabolites in a specific way. Knowing the details of how each specific compound interacts with our bodies is critical. That’s why we only recommend certain natural compounds for certain conditions and for a certain amount of time.” ~ Dr. Young Ko
Born from decades of research and developed through a collaborative effort between NewG Lab Pharma and Dr. Young Ko. Each KOfactor™ product consists of a novel combination of natural products selected to target specific cellular processes with mechanistic cohesion.
- Regular price
- Sale price
- Regular price
- Unit price
About Young Ko, PhD
Young Ko graduated with a master’s degree in Nutritional Physiology from Iowa State University in 1985. From Iowa she went to Washington State University where she graduated with a Master’s degree in biochemistry in 1989 and a PhD in Biochemistry/Biophysics in 1990. Immediately after receiving her doctorate Dr. Ko moved to Baltimore and entered the Laboratory of Peter Pedersen, PhD, at Johns Hopkins as a postdoctoral researcher.
(Left to right. Peter Pedersen, Young Ko, James Watson, Nobel Prize in Physiology or Medicine, 1962)
Revisiting a Bygone Era
Professor Pedersen had a unique background. He had been a post doctorate researcher for the reknown Albert Lehninger, who, in 1948 (along with Eugene Kennedy) made the profound discovery that the cellular organelles now called mitochondria are the site of oxidative energy production. Lehninger and Kennedy's discovery ushered in the era of modern Bioenergetics. As Lehninger’s star researcher, Professor Pedersen eventually obtained his own laboratory at Johns Hopkins University, SOM where he began to research the bioenergetic changes that occur when healthy cells transform into cancer cells. In doing so he reignited an antiquated and largely forgotten thread of research started by the Nobel Prize winning German biochemist, Otto Warburg. In 1924 Warburg discovered that cancer cells had a distinctly dysregulated metabolism which came to be known as the now famous “Warburg Effect."
Discovers New Cancer Drug
Upon entering Professor Pedersen’s lab, Dr. Ko immediately appreciated the importance of his research and the vast potential of developing drugs designed to target the Warburg Effect. Significantly, while working in the Pedersen laboratory Dr. Ko discovered a chemotherapeutic agent that targeted the Warburg Effect with extraordinary efficiency. This anticancer technology is called KAT (KoDiscovery Anticancer Therapeutics). Today, in a collaborative effort with NewG Lab Pharma, Inc., KAT is soon to enter clinical trials at several locations around the globe.
The Era of Metabolic Cancer Therapy
Researchers are now begining to fully appreciate the promise of targeting cancer through metabolism. In addition to developing novel pharmaceuticals targeted to the metabolism of cancer cells, Dr. Ko over the course of her scientific career has retained a passion for researching the potential to influence cellular metabolism with natural products.
* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.